Insight Molecular Diagnostics Inc. (IMDX): EBITDA
-$48.93M
Year ended 2025-12-31
-$47.85M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$48.93M | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$59.56M | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | -$23.54M | n/m | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | -$16.47M | n/c | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | -$52.92M | n/c | 2023-04-12, From 2021-01-01 |
| 2020-12-31 | -$29.40M | n/a | 2022-03-11, From 2020-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | -$48.93M | n/m |
| Biomerica Inc (BMRA) | 2026-05-31 | -$5.24M | n/m |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$7.80M | n/m |
| Volitionrx Ltd (VNRX) | 2025-12-31 | -$20.75M | n/m |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | -$283.99M | n/m |
| Immucell Corp (ICCC) | 2025-12-31 | $4.43M | +306.8% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | -$10.63M | n/m |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | -$431.22M | n/m |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | -$333.50M | n/m |
Compare IMDX, BMRA, AWHL, VNRX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗